Overview
Janux Q3 net loss narrows to $24.3 mln from $28.1 mln in 2024
Research and development expenses rise to $34.6 mln from $18.6 mln in 2024
Company holds $989 mln in cash and investments at end of Q3 2025
Outlook
Company expects updates on JANX007 and JANX008 in Q4 2025
Janux maintains strong cash position to support clinical programs
Result Drivers
R&D EXPENSES INCREASE - R&D expenses rose to $34.6 mln from $18.6 mln in 2024, reflecting increased investment in clinical programs
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Collaboration Revenue
$10 mln
Q3 Net Income
-$24.31 mln
Q3 Basic EPS
-$0.39
Q3 Operating Expenses
$45.25 mln
Q3 Operating Income
-$35.25 mln
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 18 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Janux Therapeutics Inc is $74.00, about 62.8% above its November 5 closing price of $27.54
Press Release: ID:nBw4GdsSsa
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
